Abstract

The study aimed to determine the associations of Peak Inspiratory Flow (PIF), inhalation technique and adherence with health status and exacerbations in participants with COPD using DPI maintenance therapy. This cross-sectional multi-country observational real-world study included COPD participants aged ≥40 years using a DPI for maintenance therapy. PIF was measured three times with the In-Check DIAL G16: (1) typical PIF at resistance of participant’s inhaler, (2) maximal PIF at resistance of participant’s inhaler, (3) maximal PIF at low resistance. Suboptimal PIF (sPIF) was defined as PIF lower than required for the device. Participants completed questionnaires on health status (Clinical COPD Questionnaire (CCQ)), adherence (Test of Adherence to Inhalers (TAI)) and exacerbations. Inhalation technique was assessed by standardised evaluation of video recordings. Complete data were available from 1434 participants (50.1% female, mean age 69.2 years). GOLD stage was available for 801 participants: GOLD stage I (23.6%), II (54.9%), III (17.4%) and IV (4.1%)). Of all participants, 29% had a sPIF, and 16% were shown able to generate an optimal PIF but failed to do so. sPIF was significantly associated with worse health status (0.226 (95% CI 0.107–0.346), worse units on CCQ; p = 0.001). The errors ‘teeth and lips sealed around mouthpiece’, ‘breathe in’, and ‘breathe out calmly after inhalation’ were related to health status. Adherence was not associated with health status. After correcting for multiple testing, no significant association was found with moderate or severe exacerbations in the last 12 months. To conclude, sPIF is associated with poorer health status. This study demonstrates the importance of PIF assessment in DPI inhalation therapy. Healthcare professionals should consider selecting appropriate inhalers in cases of sPIF.

Details

Title
Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers
Author
W. H. Kocks, Janwillem 1   VIAFID ORCID Logo  ; Wouters, Hans 2 ; Bosnic-Anticevich, Sinthia 3   VIAFID ORCID Logo  ; van Cooten, Joyce 2 ; Correia de Sousa, Jaime 4   VIAFID ORCID Logo  ; Cvetkovski, Biljana 5   VIAFID ORCID Logo  ; Dekhuijzen, Richard 6 ; Dijk, Lars 2   VIAFID ORCID Logo  ; Dvortsin, Evgeni 2 ; Garcia Pardo, Marina 7   VIAFID ORCID Logo  ; Gardev, Asparuh 8 ; Gawlik, Radosław 9 ; van Geer - Postmus, Iris 2 ; van der Ham, Iris 2   VIAFID ORCID Logo  ; Harbers, Marten 2 ; de la Hoz, Alberto 8 ; Janse, Ymke 2 ; Kerkhof, Marjan 2 ; Lavorini, Federico 10   VIAFID ORCID Logo  ; Maricoto, Tiago 11   VIAFID ORCID Logo  ; Meijer, Jiska 2 ; Metz, Boyd 2   VIAFID ORCID Logo  ; Price, David 12   VIAFID ORCID Logo  ; Roman-Rodriguez, Miguel 13 ; Schuttel, Kirsten 2   VIAFID ORCID Logo  ; Stoker, Nilouq 2   VIAFID ORCID Logo  ; Tsiligianni, Ioanna 14 ; Usmani, Omar 15 ; Leving, Marika T. 2   VIAFID ORCID Logo 

 General Practitioners Research Institute, Groningen, The Netherlands (GRID:grid.512383.e) (ISNI:0000 0004 9171 3451); University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598); Observational and Pragmatic Research Institute, Singapore, Singapore (GRID:grid.500407.6); University of Groningen, University Medical Center Groningen, Department of Pulmonology, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598) 
 General Practitioners Research Institute, Groningen, The Netherlands (GRID:grid.512383.e) (ISNI:0000 0004 9171 3451) 
 University of Sydney, Woolcock Institute of Medical Research, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Sydney Local Health District, Sydney, Australia (GRID:grid.410692.8) (ISNI:0000 0001 2105 7653) 
 University of Minho, Life and Health Sciences Research Institute (ICVS), PT Government Associate Laboratory, School of Medicine, Braga, Portugal (GRID:grid.10328.38) (ISNI:0000 0001 2159 175X) 
 University of Sydney, Woolcock Institute of Medical Research, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X) 
 Radboud University Medical Center, Nijmegen, The Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382) 
 Primary Care Respiratory Research Unit, Instituto De Investigación Sanitaria De Baleares (IdISBa), Palma de Mallorca, Spain (GRID:grid.512383.e) 
 Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany (GRID:grid.420061.1) (ISNI:0000 0001 2171 7500) 
 Medical University of Silesia, Department of Internal Medicine, Allergology, Clinical Immunology, Katowice, Poland (GRID:grid.411728.9) (ISNI:0000 0001 2198 0923) 
10  Careggi University Hospital, Department of Clinical and Experimental Medicine, Florence, Italy (GRID:grid.24704.35) (ISNI:0000 0004 1759 9494) 
11  University of Beira Interior, Faculty of Health Sciences, Covilha, Portugal (GRID:grid.7427.6) (ISNI:0000 0001 2220 7094) 
12  Observational and Pragmatic Research Institute, Singapore, Singapore (GRID:grid.500407.6); University of Aberdeen, Centre of Academic Primary Care, Division of Applied Health Sciences, Aberdeen, UK (GRID:grid.7107.1) (ISNI:0000 0004 1936 7291) 
13  Primary Care Respiratory Research Unit, Instituto De Investigación Sanitaria De Baleares (IdISBa), Palma de Mallorca, Spain (GRID:grid.7107.1) 
14  University of Crete, Department of Social Medicine, Health Planning Unit, Faculty of Medicine, Rethymno, Greece (GRID:grid.8127.c) (ISNI:0000 0004 0576 3437) 
15  Imperial College London and Royal Brompton Hospital, Airway Disease, National Heart and Lung Institute (NHLI), London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20551010
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2669793705
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.